Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 8/20 | 0.67 |
| ▸ | PDE2A | O00408 | 9/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1333032 | 1.00 | METAP2 (0.67) | METAP2PDE2APDE3APDE3BFFAR1 | |
| SCHEMBL7903221 | 0.81 | METAP2 (0.70) | METAP2PDE2APDE3A | |
| SCHEMBL17599723 | 0.80 | METAP2 (0.60) | METAP2PDE2APDE3APDE3B | |
| SCHEMBL1333041 | 0.80 | METAP2 (1.00) | METAP2PDE2APDE3B | |
| SCHEMBL17599722 | 0.80 | METAP2 (0.60) | METAP2PDE2APDE3APDE3B | |
| SCHEMBL1333295 | 0.78 | METAP2 (0.61) | METAP2PDE2APDE3APDE3B | |
| SCHEMBL1332429 | 0.78 | METAP2 (0.78) | METAP2PDE2APDE3APDE3B | |
| SCHEMBL1332435 | 0.78 | METAP2 (0.78) | METAP2PDE2APDE3APDE3B | |
| SCHEMBL1331451 | 0.77 | METAP2 (0.78) | METAP2 | |
| SCHEMBL1331456 | 0.77 | METAP2 (0.78) | METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281859-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS METAP-2 INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281859-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS METAP-2 INHIBITORS | METAP2, METAP1, XPNPEP2 | METAP2 1/4885PDE2A 2740/4885PDE3A 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.